A Phase 1 interventional study of KL0011034 injection in Healthy Participants, sponsored by Hunan Kelun Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Hunan Kelun Pharmaceutical Co., Ltd. (part of Sichuan Kelun Pharmaceutical Co.,Ltd.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To evaluate the pharmacokinetic characteristics of a single intravenous injection of KL0011034 injection in healthy non-elderly and elderly trial participants.
To evaluate the pharmacodynamics and safety of a single intravenous injection of KL0011034 injection in healthy non-elderly and elderly trial participants.
This study is a single-center, non-randomized, open-label, parallel study designed to evaluate the pharmacokinetics, pharmacodynamics, and safety of a single dose of KL0011034 injection in healthy non-elderly and elderly trial participants.
The study plans to enroll 20 trial participants, who will be assigned to the elderly group and the non-elderly group, with 10 participants in each group. After signing the informed consent form, all trial participants will undergo screening from D-14 to D-2 according to the procedures specified in the protocol. Trial participants who successfully pass screening will be admitted to the study site on Day -1 (D-1) before dosing to complete the procedures specified in the protocol. On Day 1 (D1), all trial participants will receive a single intravenous infusion of the investigational drug (KL0011034 injection), and PK blood sampling, pharmacodynamic, and safety evaluations will be performed. After completing the corresponding laboratory tests and assessments on Day 2 (D2) and upon confirmation by the investigator, participants may be discharged from the study.
Hunan Kelun Pharmaceutical Co., Ltd. is the lead sponsor of 9 studies on the registry; 6 are open to participants now.
First submitted after Hunan Kelun Pharmaceutical Co., Ltd. became part of Sichuan Kelun Pharmaceutical Co.,Ltd..
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ten elderly Trial Participants will receive KL0011034 injection
Drug: KL0011034 injection
Ten non-elderly Trial Participants will receive KL0011034 injection;
Drug: KL0011034 injection
Intravenous injection, single dose
PK parameter Cmax in plasma
Maximum peak plasma concentration (Cmax) of KL0011034 .
Time frame: 24 hours post-dose for each period
PK parameter Tmax in plasma
Time of Cmax (Tmax) of KL0011034 .
Time frame: 24 hours post-dose for each period
PK parameter AUC0-t in plasma
Area under the concentration-time curve (AUC0-t) from time zero to time "t" of KL0011034 .
Time frame: 24 hours post-dose for each period
PK parameter AUC0-∞ in plasma
AUC from time zero to infinity (AUC0-∞) of KL0011034
Time frame: 24 hours post-dose for each period
PK parameter t1/2 in plasma
Terminal-phase elimination half-life (t1/2) of KL0011034 .
Time frame: 24 hours post-dose for each period
Modified Observer's Assessment of Alertness Sedation (MOAA/S) scale
MOAA/S is a commonly used clinical sedation assessment scale, ranging from 0 to 5, which helps clinicians determine the level of sedation in patients. A score of 5 indicates full consciousness, whereas a score of 0 indicates deep coma. Lower scores correspond to deeper levels of sedation.
Time frame: Day 1 for each period
Electroencephalogram bispectrality index (BIS) monitoring
BIS is the most widely used method for the continuous monitoring of sedation depth in clinical anesthesia. BIS values range from 0 to 100, where 100 represents complete wakefulness and 0 indicates complete cortical electrical inhibition.
Time frame: Day 1 for each period
Loss of eyelash reflex
The eyelash reflex is a commonly used clinical method to assess the level of consciousness in patients. Gentle stimulation of the eyelashes with a cotton swab normally elicits a blink; absence of this response indicates loss of the eyelash reflex.
Time frame: Day 1 for each period
Modified Aldrete Scoring (Aldrete) Scale
The Modified Aldrete Score is the most widely used standardized tool for assessing discharge readiness from post-anesthesia care unit (PACU). It evaluates five parameters: activity, respiration, blood pressure consciousness, and SpO₂. Ranging from 0 to 10, the higher the score, the better the quality of recovery.
Time frame: Day 1 for each period
Number of reported Adverse Events
Safety and tolerability was assessed by the number of volunteers with adverse events.
Time frame: 24 hours post-dose for each period
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Nov 2026, 0 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: KL0011034
Hunan Kelun Pharmaceutical Co., Ltd. →